Advertisement

Topics

Epizyme Inc EPZM Financial and Strategic SWOT Analysis Review [Report Updated: 12092018] Prices from USD $125

11:22 EST 4 Nov 2018 | BioPortfolio Reports

Epizyme Inc EPZM Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.


The profile contains critical company information including:


Business description A detailed description of the company's operations and business divisions.

Corporate strategy Analyst's summarization of the company's business strategy.

SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history Progression of key events associated with the company.

Major products and services A list of major products, services and brands of the company.

Key competitors A list of key competitors to the company.

Key employees A list of the key executives of the company.

Executive biographies A brief summary of the executives' employment history.

Key operational heads A list of personnel heading key departments/functions.

Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Highlights


Epizyme, Inc. Epizyme is a biopharmaceutical company that develops novel epigenetic therapies for the treatment of cancer and other disorders. The company discovers and develops small molecule inhibitors of a class of enzymes, namely, histone methyl transferases HMTs and other chromatin modifying proteins CMPs. Using its proprietary platform and collaborations, the company has initiated the identification and development of small molecule inhibitors of CMPs and HMTs. The company is developing product candidates for the treatment of solid tumors, nonhodgins lymphoma, mesothelioma, ovarian cancer, molecularly targeted tumors and sickle cell disease. Epizyme is headquartered in Cambridge, Massachusetts, the US.


Epizyme Inc Key Recent Developments


Aug 02,2018: Epizyme reports second quarter 2018 financial results and provides business updates

Jul 23,2018: Epizyme names Dr. Shefali Agarwal as Chief Medical Officer

May 08,2018: Epizyme Reports First Quarter 2018 Financial Results and Provides Business Updates

Mar 13,2018: Epizyme Reports Fourth Quarter and Full Year 2017 Financial Results

Mar 12,2018: Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors


Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.


Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.


Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.


Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.


Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.


Note: Some sections may be missing if data is unavailable for the company

Original Article: Epizyme Inc EPZM Financial and Strategic SWOT Analysis Review [Report Updated: 12092018] Prices from USD $125

NEXT ARTICLE

More From BioPortfolio on "Epizyme Inc EPZM Financial and Strategic SWOT Analysis Review [Report Updated: 12092018] Prices from USD $125"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Epigenetics
The development and maintenance of an organism is orchestrated by a set of chemical reactions that switch parts of the genome off and on at strategic times and locations. Epigenetics is the study of these reactions and the factors that influence them. ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...